pipeline

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

Source Node:
Time Stamp: April 15, 2024 1:26 PM - Modified On: April 15, 2024 - Published By:
Source Cluster:
Republished By Plato

  Company is targeting pancreatic cancer pain with advanced nerve detection and treatment technology New York, March 12, 2024 - (Plato Data) - Benzinga has published a new article on Autonomix Medical Inc. (NASDAQ: AMIX), featuring the company's groundbreaking approach to peripheral nervous system (PNS) disorders. The Benzinga article delves into the critical role of the PNS in human health and highlights how Autonomix Medical is pioneering with its catheter-based microchip sensing array technology. The article provides a comprehensive look at how Autonomix Medical is redefining treatment protocols for nerve-related

[Mirror] Quadratic Arithmetic Programs: from Zero to Hero

Source Node:
Time Stamp: February 2, 2024 10:43 AM - Modified On: February 2, 2024 - Published By:
Source Cluster:
Republished By Plato

Vitalik Buterin via the Vitalik Buterin Blog This is a mirror of the post at https://medium.com/@VitalikButerin/quadratic-arithmetic-programs-from-zero-to-hero-f6d558cea649 There has been a lot of interest lately in the technology behind zk-SNARKs, and people are increasingly trying to demystify something that many have come to call "moon math" due to its perceived sheer indecipherable complexity. zk-SNARKs are indeed quite challenging to grasp, especially due to the sheer number of moving parts that need to come together for the whole thing to work, but if we break the technology down piece by piece then

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

Source Node:
Time Stamp: January 29, 2024 6:55 AM - Modified On: January 29, 2024 - Published By:
Source Cluster:
Republished By Plato

New York, Jan. 29, 2024 - (Plato Data) - Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug conjugate (ADC) CRB-701 in a Phase 1 trial. Citing a December data cut in patients with cancers expressing a tumor-associated antigen called nectin-4, Corbus (CRBP) said that CRB-701 led to an objective response rate (ORR) of 43%, including three partial responses. The data from the first eighteen participants who received the first six dose levels represented the readout, which was

ESG1 Partners with GMEX ZERO13 on Trading Tokenized Carbon Credits from Emissions Removals

Source Node:
Time Stamp: September 13, 2023 2:00 AM - Modified On: September 14, 2023 - Published By:
Source Cluster:
Republished By Plato

Cross-chain interoperable ESG asset trading and settlement enabled by ZERO13 as a fully integrated market distribution partner for ESG1’s highly verified, IoT-linked industrial carbon credit tokens. London and Calgary, 14 September 2023: ZERO13, a GMEX Group initiative providing a digital climate fintech aggregation ecosystem, and ESG1, a subsidiary of GuildOne providing innovative digital assets and ESG solutions built on R3’s Corda, have announced a landmark collaboration that will create an automated digital pipeline for North American industrial carbon offsets to reach high-demand markets in Europe and the Middle East. ESG1’s

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:22 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

TGI Shelly, TEAL Chimie & Energie Collaborate to Advance Green Ammonia.

Source Node:
Time Stamp: February 1, 2023 4:59 PM - Modified On: February 1, 2023 - Published By:
Source Cluster:
Republished By Plato

TGI Solar Power Group, Inc., (OTC Markets: TSPG) is pleased to announce its new management and board of directors have successfully brokered a partnership with TEAL Chimie & Energie Inc., that will launch the company’s entrance into the green energy sector. This collaboration is in line with the corporate business plan as new TGI SHELLY management is executing strategies to build long-term growth, transformational plans, digital quotient and correlation, growth acceleration, business ventures in the green sector – all of which drive shareholder value.  New Management intends to expand the

EtherMail’s Web3 email solution enabled streamlined voting for Decrypt Studios’ First Annual Crypties Awards

Source Node:
Time Stamp: January 17, 2023 3:57 AM - Modified On: January 17, 2023 - Published By:
Source Cluster:
Republished By Plato

Schaan, Liechtenstein, 17 January 2023 - EtherMail, the first Web3 email solution setting the standard for anonymous and encrypted wallet-to-wallet communication, facilitated Web3 voting for Decrypt Studios’ inaugural Crypties Awards 2022. Launched by Decrypt Studios, the Web3 production studio, The Crypties are the crypto industry’s preeminent annual awards initiative, showcasing the standout achievements of Web3 innovators. A decentralized token-gated voting system for the inaugural awards, held at Art Basel Miami in November 2022, was open to the public with a number of nominees across nine categories such as NFT Project

The Hidden Gem of Digital Assets is Hidden No More…

Source Node:
Time Stamp: August 30, 2022 4:19 PM - Modified On: August 30, 2022 - Published By:
Source Cluster:
Republished By Plato

Liti Capital’s ‘pivot’ to focus exclusively on its equity token receives an even better-than-anticipated reception from its token holders Geneva, Switzerland; August 2022: Liti Capital SA, the Swiss-based Litigation Funding specialist pioneering a new business model through the tokenization of its equity, has today provided a performance update following its recent announcement to pivot its focus away from its wLITI (‘wrapped’ LITI) token. On 1 July 2022, Liti Capital notified its token holders that it would be pivoting its focus away from its wLITI token, and insteadplacing its efforts entirely